Coen Steven P. 4

What Happened
Steven P. Coen, Chief Financial Officer of Ginkgo Bioworks (DNA), had RSUs convert into 1,805 shares on Jan 16, 2026 (587 + 156 + 1,062). On Jan 20, 2026 he sold 972 shares in an open-market transaction at $8.92 each, netting $8,667. The sale was a sell-to-cover to satisfy tax withholding tied to the vesting, not a discretionary trade.

Key Details

• Transaction dates: conversions on 2026-01-16; open-market sale on 2026-01-20 at $8.92/share (total $8,667).
• Shares acquired from conversion: 1,805. Shares sold: 972. Net shares retained from this vesting event: 833.
• Footnotes: F1 = RSU = right to one share; F2 = sale was to cover tax withholding (sell-to-cover); F3–F5 = vesting schedules for the RSU grants (includes monthly installments and specific quarterly vesting culminating 1/16/2026).
• Filing: Form 4 filed 2026-01-22 for transactions through 2026-01-16/01-20 — appears to be filed within the normal reporting window.

Context
These were conversions of restricted stock units (RSUs) into common shares, followed by a partial sale to cover required tax withholding (a routine administrative transaction). Such sell-to-cover transactions are common after vesting and do not necessarily indicate the insider’s discretionary view of the stock.